Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROIKA phase III equivalence trial of HD201 versus Herceptin in HER2-positive early breast cancer
NL-OMON46391Phase 3Withdrawn
- Sponsor
- Archemin
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of coprelotamab and trastuzumab in breast cancer, sponsored by Archemin. Planned start Jan 2018; status: withdrawn.
02
Drugs
coprelotamabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON46391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46391.